Guardant Health, Inc. (GH)

About Guardant Health, Inc.

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights. It also provides Shield blood test for colorectal cancer screening in adults. In addition, the company offers GuardantINFINITY test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development; GuardantOMNI test covers 500 genes, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications; GuardantINFORM, which provides longitudinal biological insight into tumor evolution alongside longitudinal clinical outcomes; and GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies. Further, it provides Smart Platform, which delivers multiomic insights leveraging genomic, epigenomic, and RNA-based data that are scalable from research to the clinic. Additionally, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kit fulfillment and delivery of Shield screening tests. It has a strategic collaboration with Nuvalent, Inc. for oncology drug development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.

Super investor ownership

15 of the funds we track reported a position in their latest SEC 13F filing. Largest first:

• Two Sigma, TWO SIGMA INVESTMENTS, LP$558.01M · 0.4% of book
• Baillie Gifford, BAILLIE GIFFORD & CO$342.69M · 0.3% of book
• Israel Englander, MILLENNIUM MANAGEMENT LLC$243.42M · 0.1% of book
• Ken Griffin, CITADEL ADVISORS LLC$217.47M · 0.0% of book
• D. E. Shaw, D. E. Shaw & Co., Inc.$188.39M · 0.1% of book

A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.

Politician trades in GH

We hold 7 disclosed trades in GH by members of Congress and executive-branch officials. The latest 5:

• Donald Sternoff Beyer Jr · HouseSell · $1,001 - $15,000 · traded 13 Jan 2022 · disclosed 1 Feb 2022
• Donald Sternoff Beyer Jr · HouseSell · $1,001 - $15,000 · traded 22 Dec 2021 · disclosed 1 Jan 2022
• Donald Sternoff Beyer Jr · HouseBuy · $1,001 - $15,000 · traded 2 Nov 2020 · disclosed 1 Dec 2020
• Donald Sternoff Beyer Jr · HouseBuy · $1,001 - $15,000 · traded 22 Oct 2020 · disclosed 5 Nov 2020
• Donald Sternoff Beyer Jr · HouseBuy · $1,001 - $15,000 · traded 5 Oct 2020 · disclosed 5 Nov 2020

A disclosure reports a value band, not an amount, and is due up to 45 days after the trade; some arrive later. Every filer we track, each with their own page, is on the Congress trading tracker.

Common questions